BridgeBio Historical Financial Ratios
| BBIO Stock | USD 23.42 0.18 0.77% |
BridgeBio Pharma is presently reporting on over 103 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 4.0E-4, Days Sales Outstanding of 92.54 or Invested Capital of 0.0 will help investors to properly organize and evaluate BridgeBio Pharma financial condition quickly.
BridgeBio |
About BridgeBio Financial Ratios Analysis
BridgeBio PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate BridgeBio Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on BridgeBio financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across BridgeBio Pharma history.
BridgeBio Pharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing BridgeBio Pharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BridgeBio Pharma sales, a figure that is much harder to manipulate than other BridgeBio Pharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is BridgeBio Pharma dividend as a percentage of BridgeBio Pharma stock price. BridgeBio Pharma dividend yield is a measure of BridgeBio Pharma stock productivity, which can be interpreted as interest rate earned on an BridgeBio Pharma investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to BridgeBio Pharma. There are two different methods for calculating BridgeBio Pharma invested capital: operating approach and financing approach. Understanding BridgeBio Pharma invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most ratios from BridgeBio Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into BridgeBio Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.At this time, BridgeBio Pharma's ROE is very stable compared to the past year. As of the 24th of November 2024, Graham Number is likely to grow to 28.55, though PTB Ratio is likely to grow to (4.61).
| 2023 | 2024 (projected) | Dividend Yield | 3.11E-4 | 3.98E-4 | Price To Sales Ratio | 706.43 | 741.75 |
BridgeBio Pharma fundamentals Correlations
Click cells to compare fundamentals
BridgeBio Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BridgeBio Pharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 9.02 | 144.9 | (2.77) | (0.9) | (4.85) | (4.61) | |
| Book Value Per Share | 4.53 | 0.91 | (6.0) | (8.44) | (8.25) | (7.83) | |
| Free Cash Flow Yield | (0.0702) | (0.0485) | (0.23) | (0.38) | (0.0805) | (0.0845) | |
| Operating Cash Flow Per Share | (2.41) | (3.39) | (3.45) | (2.84) | (3.24) | (3.4) | |
| Capex To Depreciation | 5.98 | 2.43 | 8.26 | 0.93 | 0.2 | 0.19 | |
| Pb Ratio | 9.02 | 144.9 | (2.77) | (0.9) | (4.85) | (4.61) | |
| Free Cash Flow Per Share | (2.46) | (3.45) | (3.78) | (2.89) | (3.25) | (3.41) | |
| Roic | (0.48) | (0.85) | (0.76) | (1.06) | (1.61) | (1.53) | |
| Net Income Per Share | (2.48) | (4.1) | (4.43) | (3.35) | (3.95) | (4.15) | |
| Cash Per Share | 5.2 | 5.15 | 5.8 | 3.2 | 2.67 | 3.17 | |
| Pocfratio | (14.53) | (20.99) | (4.84) | (2.68) | (12.45) | (13.08) | |
| Interest Coverage | (30.38) | (12.94) | (12.39) | (5.87) | (7.47) | (7.85) | |
| Capex To Operating Cash Flow | (0.0203) | (0.0188) | (0.0969) | (0.0151) | (0.002475) | (0.002599) | |
| Pfcf Ratio | (14.24) | (20.6) | (4.41) | (2.64) | (12.42) | (13.04) | |
| Income Quality | 0.81 | 0.88 | 0.79 | 0.85 | 0.87 | 0.94 | |
| Roe | (0.64) | (8.36) | 0.73 | 0.39 | 0.47 | 0.5 | |
| Ev To Operating Cash Flow | (13.49) | (21.34) | (7.51) | (5.89) | (15.04) | (15.79) | |
| Pe Ratio | (14.14) | (17.34) | (3.77) | (2.27) | (10.22) | (10.73) | |
| Return On Tangible Assets | (0.41) | (0.69) | (0.66) | (0.83) | (1.24) | (1.3) | |
| Ev To Free Cash Flow | (13.22) | (20.95) | (6.85) | (5.8) | (15.0) | (15.75) | |
| Earnings Yield | (0.0707) | (0.0577) | (0.27) | (0.44) | (0.0979) | (0.1) | |
| Net Debt To E B I T D A | 0.94 | (0.3) | (2.5) | (3.39) | (2.41) | (2.29) | |
| Current Ratio | 11.45 | 7.0 | 6.45 | 4.29 | 3.32 | 3.15 | |
| Tangible Book Value Per Share | 4.53 | 0.91 | (6.31) | (8.64) | (8.41) | (7.99) | |
| Graham Number | 14.72 | 6.73 | 24.51 | 25.32 | 27.19 | 28.55 | |
| Shareholders Equity Per Share | 3.89 | 0.49 | (6.03) | (8.51) | (8.32) | (7.9) | |
| Debt To Equity | 0.22 | 8.24 | (1.96) | (1.36) | (1.28) | (1.21) | |
| Capex Per Share | 0.0489 | 0.0637 | 0.33 | 0.0429 | 0.008023 | 0.007621 | |
| Graham Net Net | 3.71 | 0.0965 | (7.35) | (9.25) | (8.92) | (8.48) | |
| Interest Debt Per Share | 0.96 | 4.36 | 12.13 | 12.12 | 11.13 | 11.69 | |
| Debt To Assets | 0.15 | 0.68 | 1.68 | 2.74 | 3.17 | 3.33 | |
| Enterprise Value Over E B I T D A | (12.22) | (18.32) | (7.01) | (6.22) | (14.03) | (14.74) |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.